The Stop Chinese Fentanyl Act of 2025 amends the Fentanyl Sanctions Act to expand the statutory definition of “foreign opioid trafficker” to expressly include entities of the People’s Republic of China and senior Chinese officials when they produce or facilitate synthetic opioids or their precursors and fail to implement credible countermeasures. The bill also instructs the President to consider whether heads of specific Chinese agencies are traffickers and lengthens a statutory timeframe from 5 to 10 years in the Fentanyl Sanctions Act.
Separately, the bill amends the International Emergency Economic Powers Act (IEEPA) to require annual written evaluations to specified congressional committees when the President acts under IEEPA for drug-trafficking emergencies, tightens consultation language, directs more detailed regulatory cost–benefit and termination-criteria explanations, and clarifies that the Act’s sanction authorities do not permit sanctioning the importation of goods (excluding technical data). These changes shift administrative expectations for both executive rulemaking and inter-branch oversight while targeting Chinese entities and officials involved in fentanyl supply chains.
At a Glance
What It Does
It revises the Fentanyl Sanctions Act to explicitly treat certain Chinese state-affiliated entities and senior officials as potential foreign opioid traffickers and expands the statute’s scope for designation. It also amends IEEPA to mandate annual evaluations to specific congressional committees, require cost–benefit analysis in rulemaking for covered national emergencies, and changes internal timelines from 5 to 10 years.
Who It Affects
Designations and potential sanctions fall squarely on Chinese chemical producers, distributors, logistics operators, and specified senior Chinese officials tied to regulatory or law-enforcement oversight. U.S. executive-branch agencies engaged in sanctions implementation and rulemaking will face new reporting and analytic obligations, and several congressional committees gain a formal, recurring oversight feed.
Why It Matters
The bill formalizes a statutory pathway to hold foreign state-linked entities and officials accountable for precursor and synthetic opioid flows while increasing congressional oversight of emergency economic powers used for drug-control sanctions. It changes how the Executive must justify and review such authorities and limits the use of sanctions on imported goods.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill first enlarges the statutory definition of who counts as a “foreign opioid trafficker.” Rather than a generic foreign person, Congress inserts language that explicitly reaches “any entity of the People’s Republic of China” that the President finds to produce, distribute, finance, or transport specified precursor or opioid-related goods and that has failed to take “credible steps” — such as know-your-customer procedures or cooperation with U.S. counternarcotics efforts — to prevent trafficking. The definition also reaches senior Chinese officials who have regulatory or law-enforcement authority over those entities if they “aid and abet, including through intentional inaction.” That combination creates a statutory hook to target both firms and individuals tied to state apparatus.
On identification and designation mechanics, the bill amends the Fentanyl Sanctions Act to require the President to explicitly consider whether the leaders of four named Chinese agencies — the National Narcotics Control Commission, the Ministry of Public Security, the General Administration of Customs, and the National Medical Products Administration — qualify as foreign opioid traffickers. The statute also lengthens an existing statutory reference from “5 years” to “10 years,” which alters whatever timing rule existed in the amended provision (the bill changes the numeric duration in subsection (c) of the affected section).The bill layers in tighter expectations for IEEPA use when the President acts to address international drug trafficking.
For covered national emergencies tied to international drug trafficking, the President must send an annual written evaluation to specified congressional committees assessing effectiveness, stakeholder views, and suggested changes. When issuing regulations under IEEPA for those emergencies, the Executive must document cost–benefit considerations, set criteria for terminating the emergency measures, and explain in the regulatory basis how the rules resolve the emergency and why the benefits justify the costs.
The bill also replaces generic references to “the Congress” with named congressional committees for consultation and reporting.Finally, the Act contains an explicit caveat: nothing in the authorities to impose sanctions under the Act authorizes imposing sanctions on the importation of goods. The bill defines “good” broadly (articles, substances, equipment, manufactured products) but carves out technical data.
That carve-out preserves a limitation on sanctioning imported goods while preserving other measures against entities and officials.
The Five Things You Need to Know
The bill amends the Fentanyl Sanctions Act definition of “foreign opioid trafficker” to expressly include entities of the People’s Republic of China and senior Chinese officials who produce or facilitate precursor or opioid distribution and fail to take credible countermeasures.
It directs the President to assess whether the heads of four named Chinese agencies (National Narcotics Control Commission, Ministry of Public Security, General Administration of Customs, National Medical Products Administration) qualify as foreign opioid traffickers.
The bill replaces a ‘‘5 years’’ reference with ‘‘10 years’’ in the Fentanyl Sanctions Act provision it amends, changing the statutory timing in subsection (c) of that provision.
Under IEEPA, the bill requires annual written evaluations to specified House and Senate committees when the President exercises authority for a covered national emergency related to international drug trafficking.
The Act explicitly bars using its sanction authorities to target the importation of goods (defined broadly to include physical articles and equipment), while excluding technical data from that definition.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the 'Stop Chinese Fentanyl Act of 2025.' This is administrative, but it signals the bill’s focus on China-specific accountability for fentanyl and precursors.
Sense of Congress urging PRC action
Sets out nonbinding Congressional expectations for the Chinese government: identify unregulated precursor chemicals, require proper labeling, implement know-your-customer checks, and instruct specific Chinese agencies to crack down. While advisory only, this section can be used by the Executive to frame diplomatic engagement and to justify designations or sanctions actions against entities that fail to meet these benchmarks.
Expands who can be designated under the Fentanyl Sanctions Act
Substantively rewrites the statutory definition of 'foreign opioid trafficker' to (A) make explicit that Chinese state entities can be designated when they produce/distribute/finance/transport targeted goods and fail to take 'credible steps' like KYC or cooperation, and (B) allow designation of senior PRC officials who have regulatory or law-enforcement authority over those entities and who 'aid and abet' trafficking, including through inaction. Practically, this provision lowers the statutory barrier to sanctioning state-linked actors and ties failure to act to culpability; it also broadens evidence categories the Administration can rely on when making designations.
IEEPA and Trading with the Enemy Act amendments — oversight and regulatory standards
Adds an annual evaluation requirement to IEEPA for covered national emergencies related to international drug trafficking, defines which congressional committees receive the reports, and requires the President to include stakeholder views and suggestions for change. It also tightens consultation language (replacing 'the Congress' with specific committees) and requires that any IEEPA regulations issued for such emergencies include cost–benefit analysis, criteria for terminating the emergency measures, and an explanation of how the regulations resolve the emergency. These changes institutionalize a higher transparency and analytic bar for executive emergency economic actions tied to drug trafficking.
Exception for importation of goods
Creates a hard statutory exception: authorities and requirements in this Act do not include imposing sanctions on the importation of goods. The bill defines 'good' broadly (articles, substances, supplies, equipment) but excludes technical data. This limits the Administration’s leverage against import flows while leaving other tools (designations of entities/officials, financial sanctions, trade restrictions not tied to import prohibitions) available.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. law enforcement and public-health officials — they gain a clearer statutory basis to push for sanctions and designations against Chinese entities and officials implicated in precursor or fentanyl flows, potentially improving international cooperation and operational leverage.
- Congressional oversight committees named in the bill — House Foreign Affairs, Financial Services, Oversight and Government Reform, and Senate Homeland Security, Foreign Relations, Banking receive structured, recurring reports and evaluations, increasing their visibility into Executive action on drug-linked emergency sanctions.
- Compliant chemical manufacturers and traders in China and elsewhere — those who implement credible KYC and cooperate with counternarcotics efforts could avoid designation risk and be favored in diplomatic and trade discussions, creating a competitive compliance advantage.
Who Bears the Cost
- Chinese producers, distributors, logistics companies, and senior PRC officials targeted for designation — they face asset freezes, travel restrictions, and secondary sanctions risk under the Fentanyl Sanctions Act once designated.
- U.S. executive-branch agencies (Treasury, State, DOJ and others) — they must absorb new reporting, evaluation, and analytic duties under IEEPA, prepare more detailed regulatory justifications, and coordinate designations tied to state actors, which increases personnel and legal-documentation burdens.
- Diplomatic and commercial actors — U.S. trade negotiators and businesses that rely on China-based supply chains may face elevated geopolitical friction and reputational risk as the statute makes state-linked designations more likely, even though import sanctions are expressly excluded.
Key Issues
The Core Tension
The central dilemma is accountability versus leverage: the bill seeks to hold Chinese state-linked entities and officials to account for fentanyl flows by lowering the statutory barrier to designation, but doing so risks diplomatic rupture, evidentiary challenges in assigning state culpability, and reduced executive agility—while the chosen import carve-out both limits economic leverage and attempts to preserve trade relations.
The bill creates practical and legal frictions that are not self-resolving. First, the statutory reach to designate Chinese state entities and senior officials based on “failure to take credible steps” or “intentional inaction” will require the Executive to assemble evidence tying policy choices or enforcement gaps to culpability — a higher evidentiary and political threshold when targets are part of a foreign sovereign.
That raises questions about what counts as a 'credible step' (is passing a law enough, or is demonstrable enforcement required?) and how to demonstrate 'intentional inaction' by regulators without access to internal government records.
Second, the IEEPA amendments increase transparency and analytic burden but could slow responsive action. Requiring annual evaluations, stakeholder consultations, and explicit cost–benefit explanations improves oversight but may complicate the Executive’s ability to act quickly in a dynamic threat environment.
Moreover, replacing 'the Congress' with specific committees formalizes access but also concentrates oversight authority, which can politicize assessments of effectiveness. The mandate to set termination criteria for a national emergency linked to drug trafficking forces the Administration to define exit benchmarks for inherently transnational, diffuse problems.
Third, the carve-out that prohibits sanctioning the importation of goods limits a potent form of leverage—blocking imports—while still permitting designations of entities and individuals. That preserves trade flows but may blunt the immediate economic pressure on supply chains.
Finally, the bill risks diplomatic blowback: branding senior officials of another government as 'traffickers' increases the stakes for bilateral cooperation on counternarcotics and could hinder information-sharing that investigators rely on.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.